[1] Bhavsar MV, Brahmbhatt NA, Sahayata VN, et al. Papillon-Lefèvre syndrome: Case series and review of literature [J]. J Indian Soc Periodontol, 2013, 17(6):806-811. [2] Tekin B, Yucelten D, Beleggia F, et al. Papillon-Lefèvre syndrome: report of six patients and identification of a novel mutation [J]. Int J Dermatol, 2016, 55(8):898-902. [3] Jose J, Bartlett K, Salgado C, et al. Papillon-Lefèvre syndrome: review of imaging findings and current literature [J]. Foot Ankle Spec, 2015, 8(2):139-142. [4] Sreeramulu B, Shyam ND, Ajay P, et al. Papillon-Lefèvre syndrome: clinical presentation and management options[J]. Clin Cosmet Investig Dent, 2015, 7:75-81. [5] Upadhyaya JD, Pfundheller D, Islam MN, et al. Papillon-Lefèvre syndrome: A series of three cases in the same family and a literature review [J]. Quintessence Int, 2017, 48(9):695-700. [6] Albalawi AM, Hashmi JA, Alfadhli F, et al. Missense mutations in the CTSC gene in saudi families segregating Papillon-Lefèvre syndrome [J]. Ann Dermatol, 2020, 32(1):77-80. [7] Toomes C, James J, Wood AJ, et al. Loss-of-function mutations in the cathepsin C gene result in periodontal disease and palmoplantar keratosis [J]. Nat Genet, 1999, 23(4):421-424. [8] Yang Y, Bai X, Liu H, et al. Novel mutations of cathepsin C gene in two Chinese patients with Papillon-Lefèvre syndrome [J]. J Dent Res, 2007, 86(8):735-738. [9] 杨媛,白小文,刘宏胜,等. 掌跖角化牙周病综合征患者组织蛋白酶C基因的新突变[J].中华口腔医学杂志,2006,41(10):602-605. [10] Kosem R, Debeljak M, Repic LB, et al. Cathepsin C gene 5'-untranslated region mutation in Papillon-Lefèvre syndrome [J]. Dermatology, 2012, 225(3):193-203. [11] Nagy N, Valyi P, Csoma Z, et al. CTSC and Papillon-Lefèvre syndrome: detection of recurrent mutations in Hungarian patients, a review of published variants and database update [J]. Mol Genet Genomic Med, 2014, 2(3):217-228. [12] Molgaard A, Arnau J, Lauritzen C, et al. The crystal structure of human dipeptidyl peptidase I (cathepsin C) in complex with the inhibitor Gly-Phe-CHN2 [J]. Biochem J, 2007, 401(3):645-650. [13] Turk D, Janjic V, Stern I, et al. Structure of human dipeptidyl peptidase I (cathepsin C): exclusion domain added to an endopeptidase framework creates the machine for activation of granular serine proteases [J]. EMBO J, 2001, 20(23):6570-6582. [14] Korkmaz B, Lesner A, Wysocka M, et al. Structure-based design and in vivo anti-arthritic activity evaluation of a potent dipeptidyl cyclopropyl nitrile inhibitor of cathepsin C [J]. Biochem Pharmacol, 2019, 164:349-367. [15] Banerjee A, Velagaleti R, Patil S, et al. Development of potent and selective Cathepsin C inhibitors free of aortic binding liability by application of a conformational restriction strategy [J]. Bioorg Med Chem Lett, 2021, 47:128202. [16] Noack B, Gorgens H, Schacher B, et al. Functional Cathepsin C mutations cause different Papillon-Lefèvre syndrome phenotypes [J]. J Clin Periodontol, 2008, 35(4):311-316. [17] Eick S, Puklo M, Adamowicz K, et al. Lack of cathelicidin processing in Papillon-Lefèvre syndrome patients reveals essential role of LL-37 in periodontal homeostasis [J]. Orphanet J Rare Dis, 2014, 9:148. [18] Pap EM, Farkas K, Toth L, et al. Identification of putative genetic modifying factors that influence the development of Papillon-Lefèvre or Haim-Munk syndrome phenotypes [J]. Clin Exp Dermatol, 2020, 45(5):555-559. |